Early research (Phase 1)Study completedNCT01539213
What this trial is testing
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
Who this might be right for
HealthyPsoriasis
Novartis Pharmaceuticals 16